Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL5774473

O=C(CCc1cnoc1-c1ccc(C(F)(F)F)cc1)NCc1cccnc1.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
SMN1; SMN2 Q16637 3/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 3/20 0.47
HTT P42858 2/20 0.47
ALDH1A1 P00352 2/20 0.47
MAPK1 P28482 1/20 0.47
SORT1 Q99523 1/20 0.46
KMT2A Q03164 2/20 0.44
NAMPT P43490 1/20 0.44
MEN1 O00255 1/20 0.44
PAX8 Q06710 1/20 0.43
VNN1 O95497 1/20 0.43
GSK3B P49841 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL5773866 0.92 ALDH1A1 (0.48) CYP3A4CYP1A2CYP2C9CYP2C19SMN1; SMN2
Trifluoroacetic Acid SCHEMBL5773317 0.92 CYP3A4 (0.53) CYP3A4CYP1A2CYP2C9CYP2C19SMN1; SMN2
Trifluoroacetic Acid SCHEMBL5772978 0.91 GSK3B (0.52) CYP3A4CYP1A2CYP2C9CYP2C19SMN1; SMN2
Trifluoroacetic Acid SCHEMBL5772665 0.85 NPC1 (0.52) SMN1; SMN2MAPTLMNAHTTALDH1A1
Trifluoroacetic Acid SCHEMBL5775717 0.84 GSK3B (0.44) CYP1A2CYP2C9CYP2C19SMN1; SMN2KMT2A
Trifluoroacetic Acid SCHEMBL5771354 0.84 ALDH1A1 (0.49) CYP3A4CYP1A2CYP2C9CYP2C19SMN1; SMN2
Trifluoroacetic Acid SCHEMBL5774568 0.84 LMNA (0.50) SMN1; SMN2MAPTLMNAALDH1A1SORT1
Trifluoroacetic Acid SCHEMBL5771828 0.83 GSK3B (0.42) CYP3A4CYP1A2CYP2C9CYP2C19SMN1; SMN2
SCHEMBL5775471 0.82 HDAC3 (0.46) SMN1; SMN2LMNAHTTKMT2AMEN1
Trifluoroacetic Acid SCHEMBL5771101 0.81 TP53 (0.46) CYP3A4CYP1A2CYP2C9CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060084690-A1 Isoxazole derivatives MOMOSE YU 2006-04-20 US disclosed
US-7022725-B2 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-04 US disclosed
US-20040048908-A1 Isoxazole derivatives TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-03-11 US disclosed
EP-1340749-A1 ISOXAZOLE DERIVATIVES Takeda Chemical Industries, Ltd. (JP) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084690-A1 Isoxazole derivatives INSR, GPR119, INSRR CYP3A4 39/4885CYP1A2 68/4885CYP2C9 30/4885
US-20040048908-A1 Isoxazole derivatives GPR119, INSR, IRS1 CYP3A4 76/4885CYP1A2 74/4885CYP2C9 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.